What Size Laboratory Does a Growing Biotech Company Need?

The appropriate laboratory size for a growing biotech company depends on the scientific programme, team structure, equipment profile, containment requirements, data workload, support functions and expansion horizon. A biotech lab should be sized from the operating model rather than from headcount alone. Headcount provides a useful benchmark, although the decisive factors are usually wet lab intensity, instrumentation, sample handling, write up space, storage, meeting rooms, office requirements and the company’s next stage of growth.

This is particularly important in Cambridge, where competition for suitable laboratory space remains high. Cambridge University Health Partners describes the local ecosystem as including more than 30 science and technology campuses, more than 600 life science companies and three leading research active NHS Trusts. That concentration creates a demanding environment for biotech, diagnostics, medtech, data science and adjacent tech companies. Occupiers need lab space that can support current scientific work and remain useful as the company moves through funding, validation, recruitment and commercial milestones.

Recent market evidence reinforces the point. Business Weekly reported Savills data showing Cambridge office and laboratory take-up reaching 273,000 sq ft by the end of the first half of 2025, 33 percent above the five-year average. The same report identified Frontier’s 18,000 sq ft acquisition at South Cambridge Science Centre as the largest laboratory letting in Cambridge during that period. For a growing life sciences company, the property decision is therefore both technical and strategic. The right laboratory space can protect scientific momentum. The wrong size can create avoidable cost, relocation risk or operational constraint.

Begin with the science

A growing biotech company should start by defining what the laboratory has to do. A discovery biology business, a therapeutics platform, a diagnostics company, a synthetic biology team, a computational biology group and a contract research function will each use space differently.

The first step is to divide the requirement into operational categories. These normally include primary lab space, laboratory support space, write up and office areas, meeting rooms, storage, equipment rooms and shared circulation. Primary lab space covers benching, wet lab work, biosafety cabinets, fume hoods, analytical work, sample preparation and direct experimental activity. Support space may include freezers, cold rooms, incubators, autoclaves, glasswash, waste areas, chemical stores, gas storage, liquid nitrogen, clean utilities and specialist equipment zones.

The balance between these categories changes as a company grows. An early discovery team may need a high proportion of bench space and shared equipment access. A company moving toward validation may require more documentation areas, data analysis, controlled project rooms, quality processes and meeting space. A business preparing for partnerships, customer engagement or regulatory work may need stronger separation between laboratory, write up, visitor and office areas.

Use space benchmarks as a starting point

Benchmarks provide a useful initial range. University Lab Partners cites a benchmark for biotechnology labs of approximately 200 to 400 sq ft per person. PHTA’s guidance for life sciences start ups gives another useful planning point: 15 square metres per person in the lab and 8 square metres per person in office accommodation. That is approximately 161 sq ft of lab space and 86 sq ft of office space per person before the full allowance for shared support areas is considered. 

On that basis, a 20 person biotech company may require a broad planning range of 4,000 to 8,000 sq ft depending on wet lab intensity, equipment and support functions. A 40 person company may require 8,000 to 16,000 sq ft or more. A 75 person company can readily require 20,000 to 35,000 sq ft once dedicated wet lab areas, write up space, storage, equipment rooms, office accommodation, meeting rooms and growth capacity are included.

These figures are only starting points. A computational biology company with limited wet lab use may need less space per person. A wet lab intensive biotech lab with fume hoods, tissue culture, multiple instruments, cold storage and controlled workflows may need more. The correct figure comes from a detailed accommodation schedule.

Size the laboratory around equipment and workflow

Equipment is often the factor that turns a simple headcount calculation into an inadequate estimate. Freezers, incubators, centrifuges, analytical instruments, liquid handling systems, microscopy, cell culture, biosafety cabinets, fume hoods and cold storage all require space, servicing and circulation. Equipment also affects power, cooling, floor loading, data, maintenance access and safety procedures.

Workflow also drives size. Samples, reagents, waste, staff, visitors and deliveries should move through the facility in a controlled and efficient way. A company handling biological samples may need clearer separation between preparation, processing, storage, analysis and disposal. A diagnostics or regulated development business may need more documentation and quality space. A company with customer or investor visits may need meeting rooms close to reception, without disrupting laboratory operations.

Ventilation and extract requirements require particular care. The Health and Safety Executive’s guidance on local exhaust ventilation covers good design practice for hoods, ducts, air movers, air cleaners, system documentation, checking and maintenance. This matters for any occupier planning fume hoods or other extraction systems. The availability of extract routes, risers, plant capacity and maintenance access can materially affect both the suitable size and the suitable building.

Match size to funding and growth stage

Laboratory size should reflect the next operational stage, not only the current one. A seed stage company may need a smaller dedicated suite or incubator style wet lab, with access to shared equipment and a flexible commitment. A Series A company may need dedicated laboratory space, a defined office base, write up areas, better storage and a more professional meeting environment. A later stage biotech company may need larger laboratory and office accommodation, dedicated support rooms, specialist instrumentation, technical resilience and expansion rights.

A common mistake is sizing for the current team and ignoring the next milestone. Scientific teams can grow quickly after funding, technical validation or a commercial partnership. A company that takes too little space may face disruption just as its programme accelerates. A company that takes too much space too early can weaken capital efficiency. The better approach is to lease for the known requirement plus a realistic growth allowance, while securing credible options for expansion.

For many growing companies, that means searching for laboratory space that can support at least the next 24 to 36 months. The exact period depends on lease structure, funding runway, recruitment plan and technical programme. The central question is whether the laboratory can support the business through its next value inflection point.

Assess the building before finalising the size

The same square footage can perform very differently in different buildings. A purpose built laboratory building can make space more efficient because the core infrastructure has been planned for technical use. A poorly suited building may require more area, more fit out, more compromise and more time to achieve the same operational outcome.

The practical assessment should cover ventilation, extract routes, drainage, gases, power, cooling, risers, plant, loading, goods access, waste handling, digital connectivity, floor performance, acoustic separation, access control and resilience. The company should also assess the balance between lab and office areas, the quality of write up space, the number and location of meeting rooms and the ability to alter the layout as the business develops.

South Cambridge Science Centre is relevant to this issue because it offers substantial laboratory and office accommodation in the south Cambridge market. Bidwells lists South Cambridge Science Centre in Sawston as offering 20,000 to 138,252 sq ft. That scale is significant for growing biotech and life science occupiers because it allows laboratory, office, write up, meeting and support functions to be considered together, with expansion potential within a science and technology setting.

Practical sizing ranges

For planning purposes, a small biotech company of 10 to 20 people may require 2,500 to 8,000 sq ft depending on equipment intensity, wet lab use and support needs. A scaling team of 20 to 50 people may require 8,000 to 20,000 sq ft, particularly where dedicated wet lab space, write up areas, freezers, fume hoods, meeting rooms and office accommodation are required. A more established company of 50 to 100 people may require 20,000 to 50,000 sq ft or more if it needs multiple research groups, specialist equipment rooms, storage, quality systems, visitor areas and future expansion capacity.

These ranges should be tested through a room by room schedule. The schedule should identify benching, wet lab areas, dry lab areas, write up space, offices, meeting rooms, equipment rooms, storage, cold chain, waste, goods movement, reception, changing areas and circulation. It should also include a growth scenario, showing what happens when headcount increases, new equipment arrives or a new research programme begins.

The right size supports execution

The right laboratory size allows a biotech company to operate safely, recruit effectively, protect scientific momentum and progress through its next stage of growth. It gives the team enough lab space to carry out the work, enough write up and office space to manage data and documentation, enough meeting space to support decision-making and enough support space to avoid operational congestion.

For companies searching for biotech lab space or laboratory space in Cambridge, the most effective process begins with the science, converts the scientific programme into an accommodation schedule and then tests that schedule against buildings with appropriate specification and expansion capacity. South Cambridge Science Centre belongs in that search because it offers meaningful scale within the Cambridge science and technology market.

A growing biotech company should therefore treat laboratory size as an execution decision. The square footage matters, but the performance of that square footage matters more. The strongest solution is a laboratory and office environment that supports the company’s present work, its next funding or validation milestone and its long term growth path.

Purpose Built Labs Cambridge: Why Specification Matters

Laboratory specification has a direct effect on scientific productivity, capital efficiency, occupier risk and long term growth. In Cambridge, where life science, biotechnology, diagnostics, data science, engineering, dual-use research and defence sector companies compete for talent and investment, the quality of lab space carries strategic importance. Occupiers searching for purpose built labs Cambridge need buildings that can support research activity from the outset, with the right services, resilience, adaptability and technical capacity built into the fabric of the site.

Cambridge is one of the UK’s most demanding laboratory markets. Cambridge University Health Partners describes the local ecosystem as having more than 30 science and technology campuses and more than 600 life science companies. That density creates a high-performance environment for laboratory spaces. A building has to support scientific work, technical continuity, recruitment, investor confidence and future operational change. Weak specification becomes visible quickly in a cluster where occupiers compare buildings against specialist research hubs, hospital-linked campuses, university activity and venture-backed innovation businesses.

Market evidence also supports the specification case. Business Weekly reported Savills data showing Cambridge office and laboratory take-up reaching 273,000 sq ft by the end of the first half of 2025, 33 percent above the five-year average. The same report identified Frontier’s 18,000 sq ft acquisition at South Cambridge Science Centre as the largest laboratory letting in Cambridge during that period. Demand is concentrating around credible lab and office spaces because research-led occupiers need buildings that can help them move from scientific concept to validation, commercial partnership and scale.

Purpose built laboratories begin with the base building

A credible laboratory building starts with infrastructure. Benches, furniture and finishes matter, although the decisive issues are mechanical and electrical capacity, ventilation routes, risers, drainage, power resilience, equipment access, goods movement, digital connectivity, floor performance, plant space and serviceability. These factors determine how effectively an occupier can configure the space and how quickly research activity can begin.

Different occupiers have different requirements. A biotechnology company may need wet lab capability, fume hoods, controlled sample workflows and reliable drainage. A diagnostics company may need laboratory and office areas connected to write up space, data analysis and quality management processes. A medical technology company may require technical testing areas, workshop space, documentation rooms and meeting rooms for partners or customers. A dual-use sensing, biosecurity or advanced engineering company may need a more controlled arrangement of labs and offices, with project rooms, specialist equipment zones and secure collaboration areas.

This is why the phrase purpose built labs Cambridge has practical value. It signals a search for buildings where research use has been considered at design stage. A purpose built environment can reduce fit-out uncertainty, support specialist services and give occupiers a more reliable route from lease agreement to operational readiness.

Specialist services shape laboratory performance

Laboratories are service-intensive environments. Ventilation, extract, drainage, gases, power and cooling need to match the intended research activity. The Health and Safety Executive’s guidance on local exhaust ventilation covers good design practice for hoods, ducts, air movers, air cleaners, documentation, checking and maintenance. That level of technical detail illustrates why laboratory space requires disciplined planning.

For occupiers, the property questions are specific. Can the building support fume hoods where required? Are there practical extract routes? Is riser capacity sufficient? Can plant space support the intended use? Is there adequate drainage and technical servicing? Can equipment be delivered and installed without unnecessary disruption? Is there capacity to alter the balance between laboratory and office functions as the company changes?

These questions affect cost, programme and risk. When a general commercial building needs extensive adaptation for laboratory use, cost moves into design changes, fit-out complexity, delays and management time. Purpose built lab space gives occupiers a clearer starting point because the building has been planned around research activity.

Energy, resilience and continuity matter

Laboratories place heavier demands on buildings than conventional offices. Ventilation, extract, cooling, equipment loads and longer operating patterns can all affect energy use. BREEAM recognises laboratory systems as a specific energy issue where buildings with laboratory space and containment areas can assess energy-efficient laboratory systems.

This matters because occupiers need technical capability and responsible environmental performance in the same building. A state of the art laboratory building should provide capacity for research while supporting efficient operation, intelligent zoning and future adaptability. Sustainability credentials have become part of occupier decision-making because investors, partners, staff and customers increasingly expect responsible buildings as well as capable ones.

Resilience is equally important. Research companies may depend on calibrated instruments, live datasets, sensitive materials, long-running experiments or time-critical development programmes. Power, cooling, connectivity, access control and building management all affect continuity. A high-quality laboratory specification helps reduce operational risk and supports confidence during each stage of growth.

Flexibility protects growth

Science and technology companies rarely develop in a straight line. A business may begin with a small research team, then expand after funding, technical validation, regulatory progress, partnership activity or commercial traction. The mix of wet lab, dry lab, write up space, technical support areas, meeting rooms and office accommodation may change several times.

A flexible building gives occupiers room to adapt without losing momentum. It allows them to adjust the balance between laboratory and office use, add technical areas, increase project space, create more meeting rooms, improve functional separation or bring in new equipment. This matters across life science, diagnostics, medical technology, biosecurity, data science, autonomous systems, advanced engineering and defence sector companies.

The strongest laboratory buildings support multiple operating models. Some occupiers need wet lab intensity. Others need more data, dry lab and write-up activity. Some need a balanced model of labs and offices. Others need controlled technical spaces next to customer-facing meeting rooms. A building that can accommodate these different patterns has stronger long term appeal.

Cambridge location adds value when specification is strong

Cambridge’s appeal comes from the concentration of research institutions, hospitals, science and technology companies, investors, specialist advisers and skilled labour. Location helps occupiers connect into that network. Specification determines whether the building can support the work once that connection has been made.

Access to Cambridge city centre, the Biomedical Campus, research hubs and regional transport links matters for recruitment, customer visits, collaboration and senior decision-making. The south Cambridge market has become increasingly relevant because it offers access to the wider Cambridge ecosystem while providing opportunities for larger laboratory and office accommodation.

South Cambridge Science Centre sits within this context. Bidwells lists South Cambridge Science Centre in Sawston as laboratory and office accommodation ranging from 20,000 to 138,252 sq ft. Its relevance follows naturally from the specification argument. Research-led companies need lab and office spaces that can support laboratory work, write-up activity, meetings, technical operations and long term growth within reach of the Cambridge cluster.

SCSC is best understood as part of the next generation of science and technology accommodation serving the south Cambridge market. It offers a setting for occupiers that need more than standard office space and more flexibility than conventional industrial premises. For life science companies, dual-use innovators, advanced R&D teams and defence sector companies, that combination of specification, scale and location has clear appeal.

Purpose built space supports credibility

Premises influence perception. Investors, commercial partners, customers and senior recruits draw conclusions from the environment in which a company operates. A well-specified laboratory building reinforces the impression of technical seriousness, operational control and long term ambition. In Cambridge, where occupiers compete in a sophisticated and visible market, this matters.

Purpose built laboratory space can also strengthen recruitment. Scientists, engineers, data specialists and technical leaders want environments that help them work effectively. Poorly configured laboratory spaces, weak amenities, limited technical infrastructure or awkward access can make hiring and retention harder. A capable building improves the employment proposition.

For landlords and developers, specification is a core asset attribute. It widens the potential occupier base, reduces leasing friction and supports relevance as research requirements become more complex. The growth of cutting edge research in AI, diagnostics, therapeutics, biosecurity, sensing, autonomous systems and dual-use technology is increasing demand for buildings that can support mixed scientific, digital and engineering activity.

Specification should lead the search

The search for purpose built labs Cambridge should begin with the operating brief. Occupiers need to define processes, equipment, airflow, extraction, fume hoods, drainage, gases, power, cooling, data, storage, waste, goods movement, visitor access, meeting rooms and expansion scenarios before selecting space. Floor area becomes meaningful only when assessed against these requirements.

The strongest Cambridge laboratory buildings combine technical capacity, flexibility, resilience, connectivity, sustainability and access to the science and technology ecosystem. Purpose built laboratory space matters because research companies need buildings that perform under technical pressure. In Cambridge, where scientific ambition and occupier expectations are high, specification determines whether a building can support progress at the pace the market demands.

For companies searching for lab space, laboratory spaces, labs and offices or laboratory and office accommodation in Cambridge, the central issue is the same: the building must support the science. South Cambridge Science Centre belongs in this conversation because it offers a modern innovation hub for occupiers seeking purpose built laboratory and office capacity within the Cambridge science and technology market.

Defence Technology Facilities in Cambridge: Why Science and Technology Parks Are Replacing Industrial Estates

The property requirements of defence companies are changing. For many years, defence accommodation was associated with industrial estates, manufacturing sheds, logistics yards and large operational compounds. Those locations remain important for production, storage, vehicle work and heavy engineering. But the fastest growing parts of the sector increasingly need a different type of environment.

Modern defence businesses are being shaped by artificial intelligence, autonomous systems, cyber security, secure communications, robotics, space technology, advanced sensing, biosecurity and dual use engineering. These companies are not simply searching for square footage. They need high quality research and development space that can support technical teams, sensitive project work, customer engagement and future expansion.

That shift is making science and technology parks more important to the defence property market. It is also making Cambridge a stronger location for the next generation of defence and security companies.

Defence innovation is becoming more technical

The UK defence sector is moving toward faster adoption of advanced technology. Innovation is no longer confined to established defence primes or conventional suppliers. It increasingly involves specialist SMEs, university linked companies, cyber firms, AI businesses, engineering consultancies and dual use technology companies serving both commercial and defence markets.

This has changed what defence occupiers need from buildings. A company developing autonomous navigation, secure communications, cyber defence software, sensor fusion, battlefield data tools or AI enabled decision support may not require a traditional industrial estate as its first growth location. It may need secure R&D space in Cambridge, with office, laboratory, engineering and collaboration areas in one integrated setting.

For these occupiers, a facility is part of the operating model. The building must help the company recruit technical talent, protect sensitive work, host customers, support product development and scale as programmes mature. A location that only solves the immediate space requirement may become a constraint once the company moves from concept to prototype, demonstration and deployment.

Why industrial estates often fall short

Industrial estates are usually designed around practicality and cost. They can provide loading access, yard space, manufacturing areas and storage. For some defence uses, that remains appropriate. But for high value defence technology, the requirement is more complex.

A growing defence company may need dry labs, electronics benches, secure project rooms, resilient power, specialist data infrastructure, clean office space, prototype areas, meeting rooms and flexible areas that can change as programmes develop. It may also need an environment that appeals to software engineers, physicists, systems architects, cyber specialists and commercial teams.

Those needs are difficult to satisfy in many generic industrial locations. Retrofitting specialist infrastructure can be expensive. Poor amenities can make recruitment harder. Limited flexibility can force relocation at exactly the point when a company should be focused on delivery. A low headline rent can become less attractive once fit out, downtime, utilities, staff travel and future expansion are considered.

Science and technology parks are better aligned with this operating model. They are designed for organisations whose value is created through research, technical talent, intellectual property and innovation. They also provide a more credible setting for customer meetings, investor visits, grant funded projects and collaboration with universities, partners or public sector bodies.

Cambridge is well placed for defence technology

Cambridge is not a traditional defence manufacturing city. Its strength lies in deep technology, software, engineering, life sciences, communications, sensing, cyber security and applied research. That makes it highly relevant to the future of defence.

This is why searches for defence technology Cambridge and defence innovation Cambridge increasingly point toward businesses that operate across sectors. The relevant market includes cyber security companies, autonomous systems developers, engineering consultancies, medtech specialists, AI businesses, diagnostics companies and advanced hardware developers.

This broader cluster is important. Defence companies Cambridge should not be understood only as traditional military suppliers. The next generation of defence capability is more likely to come from companies working across cyber, data, sensing, communications, resilience, human performance and dual use science.

For these companies, location matters. They need access to technical people, academic networks, engineering knowledge, commercial partners and transport links. They also need buildings that can accommodate a mix of office, laboratory, write up, project and technical space.

What high tech defence occupiers need from facilities

The strongest locations for defence technology companies share several characteristics.

They provide technical flexibility. Defence companies working across software, hardware, sensors, data, communications and engineering need buildings that can adapt. A company may begin with office and dry lab space, then add testing, prototyping, secure project areas or specialist equipment.

They support controlled collaboration. Defence and security work often requires confidentiality, restricted areas and careful visitor management. But teams still need to work across disciplines. A good building allows separation where necessary without fragmenting the company.

They support recruitment. The best technical people have choices across AI, cyber, life sciences, robotics, medtech and advanced engineering. A credible science and technology environment helps make a company more attractive to the people it needs to hire.

They support customer confidence. Defence and public sector customers expect professionalism, reliability and operational discipline. A high quality R&D environment strengthens that impression.

They support expansion. Defence technology companies often grow in stages: concept, prototype, demonstration, customer validation and scale up. A building that only satisfies the first stage can become a constraint at exactly the wrong moment.

South Cambridge Science Centre and the defence property opportunity

South Cambridge Science Centre fits this changing market because it provides science and technology accommodation in a location that gives occupiers access to the Cambridge cluster without forcing them into the most constrained central areas.

The centre is in Sawston, within the south Cambridge corridor. This is an important distinction. South Cambridge Science Centre is not positioned as a traditional defence estate. Its opportunity is different. It offers a modern science and technology setting for companies whose defence relevance comes from advanced R&D, data, engineering, cyber security, sensing, communications, biosecurity or dual use technology.

For a defence technology company, that matters. Cyber, sensing, communications, autonomy, biosecurity and engineering businesses may each need a different mix of office, laboratory, write up, meeting and technical space. Flexibility is not a convenience. It is part of the operational requirement.

South Cambridge Science Centre also sits within a strengthening south Cambridge geography. Cambridge South station provides direct rail access to the Cambridge Biomedical Campus and improves connectivity between the southern cluster, Cambridge city centre and wider regional transport routes. For defence occupiers, that connectivity matters. Public sector customers, strategic partners, technical advisers, investors and senior recruits need to reach the site efficiently.

Location is not simply a map point. It affects how easily a company can work with the wider market.

A practical alternative to conventional defence property

The defence market is becoming more digital, more scientific and more closely linked to dual use technology. Industrial estates remain useful for manufacturing and logistics, but many defence technology companies now need facilities that look more like high specification R&D environments. They need buildings where research, product development, secure collaboration and technical growth can happen together.

South Cambridge Science Centre answers that brief in a way that a conventional industrial estate often cannot. It gives occupiers access to the Cambridge science and technology cluster, while offering the type of flexible accommodation needed by companies working in artificial intelligence, autonomous systems, cyber security, sensing, communications and other advanced defence applications.

For defence companies looking for property in Cambridge, the strongest locations will combine technical capacity, flexibility, transport access, talent proximity and room to grow. South Cambridge Science Centre offers a compelling south Cambridge base for companies that need more than industrial space. It provides a practical setting for defence innovation in one of the UK’s most important science and technology clusters.

Why Defence Technology Companies Are Looking Beyond Traditional Property for Secure R&D Growth

The defence sector is no longer defined only by major contractors, weapons systems and large industrial facilities. A growing share of defence capability is now being shaped by companies working in software, artificial intelligence, cyber security, autonomous systems, sensors, communications, quantum technologies, biosecurity and advanced engineering. Many of these businesses operate across both civilian and defence markets, and that dual use character is changing the property requirements of the sector.

For these companies, a conventional office is often insufficient and a traditional defence estate may be unnecessary. What many need is a high quality science and technology building that can combine laboratory space, engineering areas, secure project rooms, resilient data infrastructure, meeting space, technical services and room for growth. The defence property conversation is therefore becoming less about legacy industrial accommodation and more about research and innovation environments that support complex, fast moving technical work.

Cambridge is increasingly relevant to that conversation. The city is not a classic defence manufacturing centre. Its strength lies elsewhere. It has deep university research, strong life sciences, advanced engineering, AI capability, software expertise, communications knowledge and a dense network of specialist companies. That makes it attractive to defence technology businesses whose work sits at the edge of science, security and commercial innovation.

The government’s defence policy direction helps explain why this matters. The UK is seeking faster routes from promising technology to operational use, particularly in areas where the public sector can draw on commercial research. Defence innovation is increasingly looking beyond the established supplier base to smaller, specialist and growth stage companies. This creates demand for buildings that can support research teams, technical trials, confidential collaboration and rapid scale up.

The Defence and Security Accelerator is an example of that shift. Its model gives small companies, university linked teams and specialist technology businesses a pathway into defence problems without first becoming large prime contractors. That has practical property implications. A company developing autonomous systems, cyber resilience tools or advanced sensing may need a professional R&D base long before it needs a large manufacturing site. It may also need to move quickly from a small technical team to a larger programme group after grant funding, customer engagement or partnership activity.

Science parks and specialist technology buildings are well suited to this pattern because they are designed around growth, proximity and technical infrastructure. The most successful examples are no longer just collections of buildings. They combine workspace, specialist facilities, networking, business support, access to talent and connections into academic, clinical or public sector institutions. The rise of operators such as Bruntwood SciTech in other UK regions shows how strongly the market has moved toward managed science and innovation ecosystems rather than ordinary property provision.

For defence technology companies, that ecosystem model can be particularly valuable. These businesses often need access to engineers, data scientists, software developers, physicists, biologists, cyber specialists and commercial advisers. They also need credibility with customers, investors and public sector stakeholders. A location inside a serious science and technology cluster can therefore help with recruitment, partnership formation and market confidence.

Cambridge offers that combination in a concentrated form. It gives companies proximity to the University of Cambridge, specialist consultancies, technology founders, life sciences businesses, research hospitals, investors and experienced operators. A cyber defence company may value the software and security talent. An autonomy company may value engineering and AI skills. A biosecurity company may value the region’s life sciences base. A sensing or communications company may value the wider deep technology ecosystem.

The property requirement is correspondingly varied. Some defence technology firms may need wet laboratory space. Others may need dry lab environments, electronics benches, clean technical rooms, secure offices, demonstration areas or controlled meeting space. Many will need a blend of functions. Their premises must support confidential work without isolating teams, and technical space without losing the quality of office and collaboration areas.

This is why generic offices can fall short. A defence technology occupier may need enhanced power, cooling, data resilience, controlled access, equipment routes, workshop capability and the option to configure rooms around sensitive projects. It may also need flexible expansion so that a funded programme can grow without forcing the company into relocation. In a sector where programme timing matters, property friction can become a commercial disadvantage.

Transport is part of the calculation. Defence and dual use companies often receive visits from customers, public sector bodies, strategic partners, investors and technical advisers. They may need access to London, airports and regional networks while still drawing on Cambridge’s talent pool. The opening of Cambridge South station strengthens the appeal of the southern Cambridge corridor, particularly for companies that want access to the Cambridge Biomedical Campus area and wider city without taking space in the most constrained central locations.

South Cambridge Science Centre is a modern science and technology building that can suit defence technology and dual use companies looking for high specification, flexible R&D accommodation close to the Cambridge ecosystem. For this emerging occupier group, that distinction matters.

SCSC’s relevance lies in four practical points. It offers high quality specification, flexible laboratory and office accommodation, a strategic location close to Cambridge University and the Cambridge South cluster, and a value proposition that may be attractive compared with more constrained core locations. These characteristics align well with the needs of companies working at the intersection of defence, science and technology.

Key considerations of security, infrastructure, customer access, staff recruitment, flexibility, confidentiality and future expansion are also positively addressed. Relative cost still matters. If a building can provide access to Cambridge’s research and innovation economy at a lower rentthan the most pressured locations, it offers a compelling occupational case.

There is also a wider market trend at work. Defence innovation is becoming more scientific, more digital and more dependent on technologies developed outside the traditional defence supply chain. That means more companies are looking for premises in places associated with research, engineering, life sciences, data and advanced technology. Cambridge science parks and specialist buildings are likely to benefit from this shift because the region already contains many of the ingredients that these companies need.

For science and technology buildings in Cambridge such as SCSC this trend speaks directly to this new occupier profile. The target is not only the established defence contractor. It is the AI company working on autonomous decision support, the cyber firm developing resilient systems, the sensor business serving both commercial and defence users, the engineering company building prototypes, the biosecurity company working across health and national resilience, and the dual use technology firm that needs credibility with both private and public sector customers.

This in summary is the market story. Defence R&D is moving closer to the research and innovation economy. The companies shaping the next phase of capability often look more like advanced science and technology businesses than legacy defence occupiers. They need buildings that reflect that reality. South Cambridge Science Centre is well placed to meet that demand.

What Defines High Quality Cambridge Labs to Rent? 10 Features Every Growing Science and Technology Company Should Consider

For science and technology companies seeking the central question is whether a building can support research, people, equipment, funding milestones and future growth with minimal operational friction. Cambridge is a demanding market because the local ecosystem is unusually dense. Cambridge University Health Partners identifies six world class academic institutions, more than 30 science and technology campuses, more than 600 life science companies and three leading research active NHS Trusts in the city’s life sciences environment. That concentration creates opportunity, while also raising the standard expected of serious laboratory accommodation.

1. Why “high quality” means more than new paint

A high-quality laboratory is defined by performance rather than appearance. Fresh finishes, reception space and branding may help first impressions, but they do not determine whether a building can support specialist science. The proper assessment should examine technical infrastructure, adaptability, ventilation, compliance, energy performance, staff experience and the ability to scale.

This distinction matters in Cambridge because demand is focused on functional science space, not generic property. Cheffins reported in its Q1 2026 Cambridge market review that occupiers continue to seek established science park locations with amenities and scalable ecosystems, while prime fully fitted laboratory space has remained stable at £66 per sq ft since the end of 2025.

2. Flexible laboratory layouts

Growing companies rarely have static requirements. A company may begin with molecular biology benches, then need tissue culture, automation, analytical equipment, microscopy, freezer capacity or computational space. Flexible layouts allow a tenant to adjust the balance between laboratory benches, specialist rooms, collaboration areas and write up space without repeated relocation.

Flexibility should be visible in the building’s structure. Regular floorplates, logical riser positions, sufficient ceiling voids, robust service routes and modular benching all help a company adapt as programmes mature. A laboratory that cannot evolve can become expensive even when the initial rent appears competitive.

3. Mechanical and electrical capacity

Mechanical and electrical capacity is one of the strongest indicators of laboratory quality. Power, cooling, plant space, standby resilience, data infrastructure and equipment load capacity should be evaluated before lease negotiations are advanced. Many scientific companies discover too late that the building can accommodate office use but cannot support their equipment strategy.

The issue is becoming more important as advanced research and AI influence demand. Bidwells reported that Cambridge office market activity in 2025 was led by science and technology occupiers, with advanced research and AI having a growing effect on demand, while limited Grade A supply continued to apply upward pressure on prime rents.

4. Ventilation and specialist services

Ventilation is central to laboratory safety. Depending on the research, an occupier may need local exhaust ventilation, fume cupboards, microbiological safety cabinets, pressure control, dedicated extract routes, gas storage, drainage, cold rooms or specialist waste handling. These systems must be planned as part of the scientific operation, not treated as later fit out details.

The Health and Safety Executive states that employers should commission local exhaust ventilation systems to ensure they adequately protect people from breathing harmful substances; ventilation is a compliance and safety requirement, as well as a building specification issue.

5. Sustainability credentials

Sustainability is now a commercial consideration for laboratory occupiers. Science buildings can be energy intensive, so companies should assess building performance, carbon implications, utilities strategy and reporting standards. This is especially relevant for companies with institutional investors, pharmaceutical customers or public sector partners.

BREEAM describes whole life performance as covering the lifetime impact of a building, including resource consumption, occupant health, asset resilience and emissions. For laboratory users, the best buildings combine credible sustainability credentials with the technical capacity required for serious science.

6. Expansion opportunities

Expansion capacity should be assessed at the outset. A company may need 5,000 sq ft today and 15,000 sq ft after a successful funding round, partnership or clinical milestone. If the building cannot accommodate that growth, the company may face disruption at precisely the point when management should be focused on execution.

Savills reported that Cambridge office and laboratory take up reached 273,000 sq ft at the end of the first half of 2025, 33 percent above the five year average and 10 percent higher than the same period in 2024. It also noted that Frontier acquired 18,000 sq ft at South Cambridge Science Centre, the largest laboratory letting in Cambridge in the first half of 2025. These figures show why expansion options should be treated as a strategic requirement.

7. Office integration

Modern science companies need more than laboratory benches. They need office space, meeting rooms, write up space, data analysis areas, management offices, collaboration settings and places where investors, partners and recruits can be received professionally. The best laboratory buildings integrate these functions without weakening scientific workflow.

This is particularly important for companies working across biology, engineering, AI and data science. Scientific insight may emerge at the bench, but value creation usually requires teams to interpret results, adjust priorities, document findings, prepare regulatory material and communicate with partners. Poor office integration slows that process.

8. Staff wellbeing and amenities

Laboratory quality is also judged by the employee experience. Cambridge science companies compete for highly skilled staff, so buildings must support the working day. Natural light, good internal circulation, showers, secure cycle facilities, food options, informal meeting areas, outdoor space and reliable transport all contribute to recruitment and retention.

The importance of amenity is reinforced by Cambridge market evidence. Cheffins reported that occupiers are seeking locations with amenities and scalable ecosystems of similar organisations. That point is commercially significant because talent retention is a material operating issue for growing science and technology companies.

9. Location within the Cambridge science cluster

Location should be assessed by connectivity to talent, hospitals, academic groups, investors, suppliers and peer companies. Cambridge city centre can be valuable for recruitment, culture and access, while established science parks and southern Cambridge locations can offer specialist space, parking, campus environments and proximity to biomedical infrastructure.

Transport is increasingly relevant. The UK Government states that Cambridge South station will provide up to nine trains an hour to central Cambridge and a direct link to the Biomedical Campus. For occupiers, this improves access for staff, collaborators, executives and visitors. Importantly, it pushes further south the effective commercial radius of the Cambridge science and technology cluster.

South Cambridge Science Centre is a useful exemplar of this wider market shift. Bidwells lists South Cambridge Science Centre as leasehold laboratory and office accommodation of 20,000 to 138,252 sq ft. Savills also identified Frontier’s 18,000 sq ft acquisition there as the largest Cambridge laboratory letting in the first half of 2025. The relevance of SCSC is practical: it illustrates how the Cambridge market is adding capacity beyond the most constrained core locations while retaining access to the science cluster.

10. Total occupancy cost versus headline rent

Headline rent is only one component of cost. A lower rent may become expensive if the tenant must fund significant fit out, install additional services, upgrade power, solve ventilation problems or absorb delays. A higher rent may be justified where the building reduces capital expenditure, shortens occupation timelines, supports recruitment and provides future expansion capacity.

The correct analysis is total occupancy cost over the long term. This includes rent, service charge, business rates, utilities, fit out, maintenance, compliance, reinstatement, staff travel, operational downtime and management distraction. For venture backed companies, avoidable property cost can dilute capital that should be directed toward science, people and value creating milestones.

Conclusion

The market for high quality Cambridge labs to rent rewards buildings that do more than look modern. The strongest laboratories offer flexible layouts, robust mechanical and electrical capacity, safe ventilation, credible sustainability credentials, expansion potential, integrated write up space, staff amenities, strong cluster access and transparent long term cost discipline. For growing science and technology companies, the right laboratory is an operating platform. It should make the business more resilient, more attractive to talent and better positioned to execute within the Cambridge science ecosystem.

Why Cambridge’s Leading Biopharma Companies Are Expanding Beyond the Biomedical Campus

Cambridge’s Biomedical Campus remains one of the most important concentrations of life sciences activity in Europe. It brings together hospitals, academic medicine, pharmaceutical research, specialist suppliers and global company headquarters in a single high value district. Yet the next phase of Cambridge’s biopharma growth is increasingly spreading beyond the campus boundary. This is a sign of market strength rather than dispersal. Leading companies are expanding because the ecosystem has outgrown a single location model.

The pressure begins with demand. Cambridge University Health Partners describes the wider Cambridge life sciences ecosystem as including six major academic institutions, more than 30 science and technology campuses, over 600 life sciences companies and three research active NHS Trusts. That scale explains why the Biomedical Campus has become an anchor, while the surrounding science property market has become essential support infrastructure. A global company can gain proximity to clinical research and academic medicine on the campus, yet still require additional space elsewhere for discovery teams, data groups, manufacturing support, commercial functions or growth stage laboratory work.

AstraZeneca illustrates the power and pressure of the campus model. Its Cambridge base is home to the company’s global corporate headquarters and flagship research and development facility, The Discovery Centre. AstraZeneca says the site connects it with academic and industry networks, scientific talent and collaboration opportunities. The Discovery Centre also houses more than 2,000 scientists working in drug discovery and development. This is precisely the type of anchor presence that makes the campus globally significant, yet it also shows why nearby capacity becomes critical. When one company alone can concentrate thousands of highly skilled people around a single research hub, the wider area must provide room for suppliers, partners, spinouts and related occupiers.

The issue is partly a shortage of modern laboratory space, and partly a shortage of the right kind of space in the right locations. Cambridge has seen waves of new development, yet many biopharma occupiers need specialist buildings that can adapt to changing scientific workflows. Traditional offices cannot simply absorb biology, chemistry, sequencing, automation and data intensive work without major technical compromise. Bidwells reported that Cambridge laboratory take-up reached a seven year high in 2023 after the delivery of new lab stock, while a significant shortfall of 850,000 sq ft still persisted. More recent market data from Savills showed Cambridge office and laboratory take up reaching 273,000 sq ft by the end of the first half of 2025, 33 percent above the five year average.

That demand is changing in character. Modern biopharma companies often need buildings that can flex between wet lab, dry lab, office, collaboration, automation and computational work. The boundary between biotech and technology is becoming less useful as companies use AI, genomics, high throughput screening and advanced analytics to accelerate discovery. Illumina’s Cambridge Solutions Centre, located within its European headquarters, is used as a working lab for training, collaboration studies and testing new technologies. That operating model needs more than generic accommodation. It needs adaptable, technically credible space connected to a skilled labour market.

This explains why the wider Cambridge science market has become strategically important. The Biomedical Campus remains the centre of clinical gravity, while places such as Granta Park, Cambridge Science Park and emerging south Cambridge locations provide additional formats for growth. Bicycle Therapeutics, for example, is based at Granta Park in Great Abington, outside the Biomedical Campus, while Illumina Cambridge Limited is registered at Granta Park. These locations demonstrate that companies can remain inside the Cambridge talent and investor ecosystem while operating beyond the campus itself.

GSK adds another dimension. The NIHR Cambridge Biomedical Research Centre describes the campus as combining patient care, world class institutes and drug discovery through GlaxoSmithKline’s Clinical Unit and AstraZeneca’s global research headquarters. GSK has also announced a five year collaboration with the University of Cambridge in kidney and respiratory disease, with a focus that includes AI enabled research. This is the Cambridge model at work: pharmaceutical companies, university science and clinical research interacting across institutional boundaries. Expansion beyond the campus supports that model by giving companies more ways to place teams close to the ecosystem without forcing every function into the same constrained district.

Abcam shows how the campus has historically attracted companies seeking a headquarters identity within the biomedical cluster. The company moved to a purpose-built global headquarters on Discovery Drive at the Cambridge Biomedical Campus in 2019. Its later acquisition by Danaher for approximately $5.7 billion reinforced the international value attached to Cambridge life science assets. The lesson for the next generation of companies is clear: campus presence can create credibility, yet future growth may require a wider real estate strategy across Cambridge and South Cambridgeshire.

South Cambridge Science Centre

Transport is another reason expansion is spreading. A single dense campus can become less efficient if staff, visitors and collaborators struggle to reach it. New capacity encourages diffusion. According to the Department for Transport, the new Cambridge South station will provide up to nine trains an hour to central Cambridge and a direct link to the Biomedical Campus which is bound to encourage life science and pharma organisations to locate further to the south of Cambridge. The government also states that the Biomedical Campus contributes £4.7 billion annually to the UK economy, with that figure expected to rise to £18.2 billion by 2050 alongside a doubling of current employees. Growth on that scale requires a broader geography, with connected sites that can absorb demand and keep the labour market accessible.

Flexible buildings are central to that future. A young therapeutics company may need fitted laboratory space quickly, then require more technical capacity after funding. A genomics or diagnostics company may need a higher ratio of data work to wet lab work. A pharmaceutical company may want collaboration space near academic groups while keeping other functions elsewhere. A successful building must therefore offer adaptability, technical resilience and expansion logic. The Greater Cambridge Growth Sectors Study identified the need for high quality modern workspaces, larger cluster settings, amenities and good public transport, while recognising that even successful life science locations such as the Biomedical Campus and Cambridge Science Park must evolve.

South Cambridge Science Centre is relevant because it addresses one of the core problems facing the market: companies need additional modern capacity close enough to Cambridge’s talent and clinical infrastructure to be useful, while offering a practical alternative to the most constrained campus locations. Independent market reporting from DTRE stated that phase one of Abstract’s South Cambridge Science Centre brought about 138,500 sq ft of highly flexible laboratory space to the Cambridge market. Savills also identified Frontier IP’s approximately 18,000 sq ft acquisition at South Cambridge Science Centre as the largest Cambridge laboratory letting in the first half of 2025. That matters because SCSC is a response to a real expansion problem: the market needs credible locations where growing science companies can secure space without losing connection to Cambridge’s biomedical economy.

The Frontier IP transaction also shows how demand is shifting toward ecosystems inside buildings. Frontier IP announced a strategic partnership to open an innovation hub at South Cambridge Science Centre, with space intended to support early-stage companies in deep technology and life sciences. This is a useful model for Cambridge’s next phase because growing companies often need more than square footage. They need commercialisation support, investor visibility, peer companies and access to technical talent. SCSC’s value is therefore further strengthened when understood as part of a broader expansion pattern around south Cambridge, rather than solely as a lower-cost alternative to the Biomedical Campus.

Access to Cambridge talent remains the decisive thread connecting all of these decisions. The University of Cambridge, the hospitals, pharmaceutical companies, sequencing specialists, platform biotechs and research institutes create a labour market that cannot be replicated quickly. Companies expand beyond the Biomedical Campus because they want to stay near that talent while finding buildings that fit their next operational stage. That is why the city’s growth is becoming more polycentric. The campus provides the clinical and institutional centre of gravity. The surrounding science parks and laboratory schemes provide the space, flexibility and resilience needed for future growth.

The strategic conclusion is straightforward. Cambridge’s leading biopharma companies are expanding beyond the Biomedical Campus because success has created pressure. AstraZeneca, GSK, Illumina, Abcam and Bicycle Therapeutics each demonstrate different aspects of the same market: global scale research, clinical collaboration, genomics infrastructure, commercial headquarters capability and specialist platform science. The next stage of growth depends on modern lab space, flexible buildings, better transport and locations that can support companies as they mature. South Cambridge Science Centre fits into that story as a practical solution to the capacity challenge, adding another route for companies that need Cambridge access without being limited to the campus itself.

Why International Biotech Companies Choose Cambridge for Their UK Expansion Location

International biotech companies choosing a UK expansion location are making a decision about execution risk. The question is where a company can recruit faster, form credible research partnerships, access clinical insight, secure appropriate laboratory space and build relationships with investors and pharmaceutical companies. Cambridge remains one of the UK’s strongest answers because it combines scientific depth, clinical infrastructure, specialist property, global reputation and commercial networks in a compact geography.

The first reason is the concentration of life sciences capability. Cambridge University Health Partners reports that the local ecosystem includes six major academic institutions, more than 30 science and technology campuses, over 600 life sciences companies and three research active NHS Trusts. For overseas management teams assessing biotech expansion UK options, that density matters. It gives a new entrant immediate access to a mature market of researchers, clinicians, founders, service providers and technical talent rather than requiring the company to assemble those networks from the beginning.

The wider Cambridge business base strengthens that position. The University of Cambridge states that the Cambridge Cluster contains more than 4,500 knowledge intensive firms, employs more than 75,000 people and generates £25 billion in turnover. Those figures show that Cambridge is more than a university city with strong science. It is a functioning innovation economy with the supporting skills required to help companies move from discovery into growth.

For international biotech companies, this matters because expansion is rarely a single function decision. A company may begin with a research team, then need senior hires, intellectual property support, regulatory advice, finance leadership, clinical operations expertise and commercial partners. Cambridge gives management teams a deeper bench across those functions than most UK locations. That depth helps make a UK operation more than a small satellite office.

The presence of major pharmaceutical companies also gives Cambridge strategic credibility. AstraZeneca identifies Cambridge as the home of its global corporate headquarters and flagship research and development facility, The Discovery Centre. The company says its Cambridge base connects it with academic and industry networks, scientific talent and collaboration opportunities. For a board considering a UK biotech headquarters, that is an important signal. It demonstrates that Cambridge can support global leadership, not only early stage research.

BioNTech provides a more recent example of Cambridge’s international pull. In 2025, the German immunotherapy company announced plans for a Cambridge R&D centre focused on genomics, oncology, structural biology and regenerative medicine, with capacity for more than 90 highly skilled scientists. These are cutting edge disciplines that depend on advanced research capability and specialist recruitment. BioNTech’s decision illustrates why Cambridge remains attractive to companies working at the frontier of modern medicine.

Clinical proximity is another major driver. The Cambridge Biomedical Campus reported in 2025 that it contributes £4.7 billion annually to the UK economy. Its value to biotech companies lies in the combination of hospitals, research institutes, academic expertise and industry presence. Companies developing innovative products need clinical insight early, especially where trial design, biomarkers, patient stratification and translational evidence will influence investor confidence.

This is particularly relevant because clinical trials remain a competitive pressure point for the UK. The ABPI’s 2025 clinical trials report recorded a 35.7 percent increase in UK industry trial initiations in 2024, rising from 426 in 2023 to 578 in 2024. The same report also highlighted continuing weaknesses in patient recruitment and trial delivery. For international companies, this makes location choice more important. Strong research hospitals, experienced investigators and translational networks can improve the practical conditions for clinical development.

The national policy context is supportive, while still demanding. The UK Government’s Life Sciences Sector Plan states that pharmaceutical R&D accounted for 17 percent of all UK business R&D in 2023, the largest share of any product area. The plan also recognises that the UK is strong in discovery and weaker in commercialisation and adoption. Cambridge helps address that imbalance because it combines discovery science with company formation, clinical infrastructure, specialist investors and connections to pharmaceutical companies.

Cambridge laboratory space is therefore a strategic issue rather than a simple facilities requirement. Biotech companies need different types of space at different stages. A platform company may require a blend of wet lab, dry lab and computational space. A therapeutics company may need specialist utilities, containment, equipment routes and room to expand. A diagnostics or engineering biology company may need adaptable technical infrastructure as experiments move from proof of concept to repeatable development.

South Cambridge Science Centre

Independent market evidence shows continuing demand. Knight Frank reported that science and innovation leasing across the Golden Triangle reached 234,779 sq ft in the first quarter of 2026, which was 43.2 percent above the five year average and 6 percent ahead of the same period in 2025. This suggests that high quality laboratory and innovation space remains in demand despite a more selective financing environment. For companies entering Cambridge, securing the right premises at the right stage can influence capital efficiency as well as operational performance.

CBRE’s Cambridge life sciences market profile describes the city as one of Europe’s most advanced life sciences hubs, with real estate infrastructure that supports the innovation lifecycle from discovery through translation and commercialisation. That breadth is important. International companies are not looking only for a building. They are looking for a place where research, clinical development, hiring and commercial engagement can happen within the same operating environment.

Transport is becoming a more visible part of that equation. Network Rail says Cambridge South station is expected to open to the public on 28 June 2026 and will improve connectivity to the biomedical campus and the wider region. For international biotech companies, this has practical value. Easier movement supports recruitment, site visits, investor meetings, hospital access and collaboration between teams.

South Cambridge Science Centre fits into this wider pattern as part of the market’s response to demand for additional specialist space around the southern Cambridge corridor. This article does not rely on SCSC website material. The relevant independent evidence is market based. Savills identified Frontier IP’s 18,000 sq ft acquisition at South Cambridge Science Centre as the largest laboratory letting in Cambridge during the first half of 2025. Savills also noted that the space would support incubation activity for Frontier’s portfolio companies.

The Frontier IP transaction is significant because it links property demand with company formation. Frontier IP announced a strategic partnership to create a Cambridge innovation hub and stated that it expected portfolio companies and other early stage businesses to use the facility. For the wider Cambridge science park market, this is a positive signal. It shows that specialist locations are being used to support deep technology and life sciences businesses, rather than simply absorbing surplus office demand.

The southern Cambridge corridor benefits from this type of additional capacity. Companies that want proximity to the biomedical campus, access to Cambridge South connectivity and room to scale need credible options beyond the most constrained central locations. SCSC is relevant because it adds choice to the market in a location that can support laboratory users, commercialisation teams and growth stage occupiers. The point is measured but important: Cambridge’s appeal improves when the city can offer more than one route into the ecosystem.

For international biotech companies, Cambridge also offers reputational compounding. Each major company, university spinout, clinical research group, investor backed platform and specialist science location reinforces the decision case for the next entrant. That cumulative effect is difficult for emerging clusters to copy. It allows new arrivals to operate in a market where counterparties already understand life sciences risk, financing cycles, translational research and the requirements of regulated innovation.

The conclusion is clear. Cambridge attracts international biotech companies because it reduces multiple expansion risks at once. It offers talent, clinical infrastructure, pharmaceutical partners, investors, research excellence, specialist property and improving transport links. For boards considering biotech expansion UK strategy, Cambridge is more than a prestigious postcode. It is a practical environment for turning scientific ambition into clinical trials, partnerships and innovative products.Savills reported that Frontier IP’s 18,000 sq ft deal at South Cambridge Science Centre was Cambridge’s biggest laboratory lease in the first half of 2025.

What Biotech Investors Look for in a Science Park

What separates a science park that simply provides laboratory space from one that materially improves the investment case for biotech companies?

For biotech investors, the answer is increasingly clear. A science park is not assessed only as a property asset. It is assessed as part of the value creation infrastructure around a company. The right environment can reduce scientific execution risk, hiring risk, capital inefficiency, regulatory uncertainty, translational delay and exit risk. In the life sciences sector, where companies can spend years progressing from discovery to clinical validation, the quality of the location can influence whether promising research and development becomes investable evidence.

This is why investors now look beyond prestige, building design and postcode. A strong UK science park must help companies reach value inflection points faster, preserve capital for science and create the conditions in which technical progress can become commercial value. In a more selective funding market, that distinction matters.

The investment context is important. UK biotech raised £1.79 billion of venture capital across 58 deals in 2025, according to the BioIndustry Association. The UK retained its position as Europe’s leading national biotech market, representing 30 percent of European venture financing. The same report described 2025 as one of the most selective investment climates in a decade. In Q1 2026, the BIA reported £552 million of total equity financing for UK biotech, with venture capital rising 17 percent quarter on quarter to £516 million and deal activity increasing to 25 VC transactions. These figures show that capital remains available, but investors are demanding greater discipline, stronger evidence and clearer routes to scale.

The first factor investors assess is talent access. Biotech companies are often talent constrained before they are space constrained. Investors therefore look for science parks close to universities, hospitals, data science teams, experienced founders, technical operators, regulatory advisers and repeat executives. Hiring for translational biology, medicinal chemistry, bioinformatics, clinical operations, quality systems, genetic engineering and platform technology is highly competitive. A park that gives companies access to this talent pool can reduce recruitment friction and improve execution speed.

Cambridge illustrates this point clearly. Cambridge University Health Partners identifies the city as having six world class academic institutions, more than 30 science and technology campuses, more than 600 life sciences companies and three leading research active NHS Trusts. The University of Cambridge reports more than 4,700 knowledge intensive firms, more than 75,000 people employed by those firms and £25 billion in annual turnover generated by knowledge intensive companies in the city region. For investors, these numbers indicate more than regional strength. They point to a dense operating environment where specialist expertise, clinical insight and commercial experience are concentrated.

The second factor is translational proximity. Investors want to know that a company can move from discovery science to validated programme without losing time in fragmented networks. This is particularly important for companies working in human health, where patient biology, clinical relevance, diagnostics, biomarkers and trial design can determine whether a programme survives due diligence. A strong science park gives companies access to clinicians, patient cohorts, hospital systems, contract research partners, diagnostics specialists and senior scientific advisers. A park outside a serious biomedical ecosystem may offer attractive rent, but it may not provide the clinical adjacency that improves a company’s probability of success.

The third factor is state of the art technical infrastructure. Biotech is no longer a single category with one standard space requirement. AI enabled drug discovery companies may need more computational infrastructure and less wet lab space. Cell therapy companies may need specialist containment, cold chain capability, clean room pathways and resilient utilities. Synthetic biology and genetic engineering companies may require carefully configured laboratories, extraction, gases, waste handling and advanced equipment access. Companies working on food production may need biological testing capacity, fermentation capability or pilot scale development environments. Investors therefore favour science parks that can support multiple operating models rather than forcing companies into rigid space formats.

JLL’s 2025 life sciences real estate analysis stated that AI native biotechs now account for one sixth of all biotech venture capital deals. It also reported that those companies lease roughly one third less space per employee than traditional biotechs and show a lower lab to office ratio of 45 to 55. For investors, this is a crucial signal. The strongest parks are those that can accommodate wet lab science, dry lab work, data intensive discovery, automation and future expansion without creating unnecessary capital burden.

The fourth factor is capital efficiency. In a selective market, every lease decision affects runway. Investors will scrutinise whether a company is committing to too much space too early, paying for unnecessary fit out or accepting inflexible obligations before its science has been de risked. A strong UK science park offers phased growth, adaptable laboratories, shared equipment options, practical expansion routes and reduced relocation risk. Real estate may not be the central investment thesis, but poor real estate decisions can damage that thesis by diverting capital away from experiments, talent, intellectual property and clinical progress.

The fifth factor is proof of occupier demand. Investors look for evidence that a park is attracting relevant companies rather than simply marketing itself as a life sciences location. Leasing data can provide that signal. Cushman & Wakefield reported that Golden Triangle take up reached 242,200 sq ft in Q1 2026, 33 percent above the five year quarterly average. It also reported prime quoting rents of £77 per sq ft in Cambridge, £70 per sq ft in Oxford and £140 per sq ft in London. In the same quarter, 471,700 sq ft of lab space completed across the Golden Triangle, with a further 3.1 million sq ft under construction. These figures show why investors must distinguish genuine cluster strength from undifferentiated laboratory supply.

The sixth factor is ecosystem quality. Biotech investors favour parks where companies can meet venture funds, pharma scouts, corporate partners, patent advisers, grant specialists, technical consultants and experienced board members within the same regional network. The best ecosystems increase the surface area for strategic partnerships and reduce the founder’s dependence on cold outreach. They also help companies learn from peers facing similar technical, regulatory and commercial milestones.

South Cambridge Science Centre is a positive example of this broader shift. The centre describes itself as a 138,484 sq ft gross internal area science park with laboratories and offices, designed around sustainability, flexibility and energy efficiency. It is located close to Cambridge South railway station, the Cambridge Biomedical Campus and the University of Cambridge. That combination of laboratory provision, transport connectivity and cluster adjacency aligns with what investors increasingly want from scale up infrastructure.

The centre has also gained market validation through occupier activity. In June 2025, Frontier IP announced a strategic partnership with Abstract Mid Tech to create an innovation hub at South Cambridge Science Centre, taking a 20 year lease for start up and early stage science and technology companies. Frontier IP said it intends to sublet space to portfolio companies and other innovative businesses aligned with deep technology and life sciences. Savills later identified Frontier’s 18,000 sq ft acquisition at South Cambridge Science Centre as the largest laboratory letting in Cambridge during the first half of 2025. For investors, this is the type of signal that matters because it connects real estate with commercialisation capacity.

The seventh factor is policy and funding alignment. Biotech investors prefer parks located in regions supported by national strategy, infrastructure investment and specialist funding programmes. The UK Government’s Life Sciences Sector Plan recognises that emerging life sciences firms can struggle to raise capital, particularly at Series B and later stages. It sets out British Business Bank commitments including an additional £4 billion of Industrial Strategy Growth Capital intended to crowd in £12 billion of private sector capital. It also confirms the £520 million Life Sciences Innovative Manufacturing Fund, designed to support domestic manufacturing capacity in medicines, diagnostics and medtech. Policy support does not replace company level diligence, but it can strengthen the long term attractiveness of a cluster.

The eighth factor is sustainability and operational resilience. Life sciences buildings are resource intensive, so investors increasingly assess energy performance, grid resilience, carbon reporting, water use and continuity planning. Sustainability is not a reputational extra. It affects operating cost, institutional investor reporting, occupier procurement and future proofing. Parks with credible sustainability credentials and resilient infrastructure are better positioned to support companies as they scale.

The ninth factor is exit optionality. Investors want to know whether companies in a park are visible to acquirers, pharma partners, later stage funds and strategic collaborators. In biotech, liquidity can come through M&A, licensing, platform partnerships or public markets. Since IPO markets have remained constrained, strategic visibility has become more important. The BIA noted that Q1 2026 had no UK biotech IPOs and that IPO inactivity has persisted since 2022. That reinforces the importance of ecosystems that connect companies to private capital, strategic partners and potential acquirers.

The conclusion is straightforward. Biotech investors look for science parks that behave like value creation platforms. The strongest parks combine talent density, clinical adjacency, state of the art infrastructure, capital efficient occupancy, credible occupier demand, commercial networks, policy alignment, sustainability and exit visibility. A science park that merely provides laboratory space is exposed in a selective market. A science park that helps companies turn promising science into investable evidence becomes part of the investment case itself.